Latest Biotech News

A first-in-human peptide vaccine targeting common mutant KRAS variants showed an early proof of concept for pancreatic cancer interception in high-risk patients. Researchers at Johns Hopkins...

GSK moved to stop work on camlipixant for refractory chronic cough after mixed Phase 3 results undermined the drug’s late-stage momentum. In the Calm-1 and Calm-2 trials, the 50 mg twice-daily...

Researchers reported in Science a new AI-designed strategy for building functional CRISPR-like nucleases that can rival or outperform natural enzymes. The work describes structure- and...

Sarepta announced it is launching an additional Phase 3 trial for Elevidys (delandistrogene moxeparvovec) to address European regulator concerns after the EMA denied marketing authorization last...

Dimerix acquired Mission Therapeutics’ acute kidney injury candidate in a deal structured with an upfront payment plus milestone funding. Dimerix will pay $5 million upfront and commit to as much...

Juno Bio raised $3.8 million and opened a CLIA-certified sequencing lab in Oakland to scale its vaginal microbiome assay. The company said its test analyzes approximately 10,000 bacteria and fungi...

Jasper Therapeutics announced a merger with Nasdaq-listed Kira Pharmaceuticals as it seeks to rebound from earlier clinical setbacks. The transaction is paired with a concurrent licensing deal...

Insmed provided new open-label extension data for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension. The company reported that patients in the treated arm...

A genetic study published in Science Advances linked a subtype of primary idiopathic hyperhidrosis to a neurocutaneous NaV1.8 channelopathy. Researchers from Vrije Universiteit Brussel and...

BIOCENTURY reported that advisory committees for peptides and RP1 are poised to test FDA credibility over composition and conflict-of-interest disclosures in compounding-related oversight. The...

The FDA approved Merck’s Lipfendra (enlicitide), the first oral PCSK9 inhibitor, for lowering LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial...

GSK ended development of camlipixant after mixed results in two Phase 3 trials in refractory chronic cough. In Calm-1, the 50 mg twice-daily dose met its primary endpoint at week 12, but Calm-2...

Sarepta launched a second Phase 3 trial for Elevidys (SRP-5053), aiming to address the EMA’s marketing authorization denial after the EMBARK evidence package fell short on efficacy in movement...

Biopharma dealmaking accelerated in the first half of 2026, capping a record-breaking M&A run with June’s $25.7 billion haul. Through H1, deal value reached $170.11 billion, surpassing prior...

A Phase 1 study reported that an off-the-shelf mutant KRAS peptide vaccine for pancreatic cancer interception generated KRAS-specific T-cell responses in 90% of high-risk participants. In the...

Leica Biosystems, part of Danaher, agreed to buy Statlab Medical Products to broaden Danaher’s diagnostics and anatomical pathology portfolio with additional consumables and instruments. The deal...

Juno Bio raised $3.8 million and opened a CLIA-certified sequencing lab in Oakland to scale its vaginal microbiome assay. The company said the test analyzes about 10,000 bacteria and fungi and...

Dimerix agreed to buy Mission Therapeutics’ stalled, Phase 2-ready acute kidney injury candidate for $5 million upfront, with up to $287 million in milestones. The transaction, described as...

Researchers reported that blood ctDNA profiling can better select patients with metastatic castration-resistant prostate cancer (mCRPC) for radium-223 (^223Ra) radiopharmaceutical therapy. A study...

Chai Discovery raised $400 million in Series C financing, pushing the AI drug-discovery firm’s valuation to $3.8 billion and signaling continued investor confidence in end-to-end model-driven...